61533-67-3

Upstream product

• 849585-22-4 LACTIC ACID 
• 95-55-6 2-amino-phenol 
• 122433-29-8 1-(benzo[d]oxazol-2-yl)ethanone 
• 615-18-9 2-chloro-1,3-benzoxazole 
• 64-17-5 ethanol 
• 124855-83-0 5a,6,11a,12-Tetrahydro-5a-methyl<1,4>benzoxazino<3,2-b><1,4>benzoxazine 

Downstream Products

• 122433-29-8 1-(benzo[d]oxazol-2-yl)ethanone 
• 124855-89-6 2-<1-(2-Benzoxazolyl)ethylidenamino>phenol 
• 1315309-31-9 (S)-1-(benzoxazol-2-yl)ethan-1-ol 
• 1308372-81-7 C₁₈H₁₇NO₃ 
• 1308372-75-9 C₁₈H₁₇NO₃ 
• 1315309-26-2 C₂₃H₁₉NO₃ 

Relevant academic research and scientific papers

Direct α-Arylation of Alcohols with Aryl Halides through a Radical Chain Mechanism

Alcohols were found to be arylated directly at their α-C?H bond with aryl halides in the presence of a base and a substoichiometric amount of t-BuOOt-Bu through a homolytic aromatic substitution mechanism. (Figure presented.).

Benzoxazole-2-ethyl oxime derivate, preparation method and application thereof

The invention provides a benzoxazole-2-ethyl oxime derivate. The benzoxazole-2-ethyl oxime derivate is as shown in a formula (I) or a formula (II), wherein X1 and X2 are independently selected from NHor O; R1 and R3 are independently selected from H, F, Br or C1; R2 is selected from C1-C10 alkyl, substituted C1-C10 alkyl, phenyl or substituted phenyl; the substituted group of the substituted C1-C10 alkyl is selected from phenyl or halogen. Compared with the prior art, the benzoxazole-2-ethyl oxime derivate as shown in the formula (I) or the formula (II) is capable of obviously reducing anklejoint swelling degree and serum uric acid level of a rat with acute gouty arthritis, and is high in NLRP3 and TLR4 dual inhibition activity; the effect of the benzoxazole-2-ethyl oxime derivate is obviously prior to that of positive control dexamethasone; the benzoxazole-2-ethyl oxime derivate is applicable to preparation of drugs for treating hyperuricemia or acute gouty arthritis, and is small in side effect, and high in safety. (The formula is shown in the description).

Development of benzoxazole deoxybenzoin oxime and acyloxylamine derivatives targeting innate immune sensors and xanthine oxidase for treatment of gout

Both the inhibition of inflammatory flares and the treatment of hyperuricemia itself are included in the management of gout. Extending our efforts to development of gout therapy, two series of benzoxazole deoxybenzoin oxime derivatives as inhibitors of innate immune sensors and xanthine oxidase (XOD) were discovered in improving hyperuricemia and acute gouty arthritis. In vitro studies revealed that most compounds not only suppressed XOD activity, but blocked activations of NOD-like receptor (NLRP3) inflammasome and Toll-like receptor 4 (TLR4) signaling pathway. More importantly, (E)-1-(6-methoxybenzo[d]oxazol-2-yl)-2-(4-methoxyphenyl)ethanone oxime (5d) exhibited anti-hyperuricemic and anti-acute gouty arthritis activities through regulating XOD, NLRP3 and TLR4. Compound 5d may serve as a tool compound for further design of anti-gout drugs targeting both innate immune sensors and XOD.

Compositions containing five-membered unsaturated heterocyclic structure of the α, β unsaturated ketone compound and its preparation method and application

The invention provides alpha, beta unsaturated ketone compounds containing benzo five-membered unsaturated heterocycle structures as well as a preparation method and an application and use of the compounds. The alpha, beta unsaturated ketone compounds containing the benzo five-membered unsaturated heterocycle structures have the structure of a formula (I). In addition, the invention further provides a method for preparing the compounds and a pharmaceutical composition containing the components as active components. In vitro activity tests show that the compounds provided by the invention show a remarkable inhibiting effect on tumor cells. Therefore, the invention lays a foundation for lucubrating and developing anti-tumor medicines in the future and meanwhile further provides a new technical means for treating tumor diseases.

Sunflow: Sunlight Drives Fast and Green Photochemical Flow Reactions in Simple Microcapillary Reactors – Application to Photoredox and H-Atom-Transfer Chemistry

“Sunflow“ – The combination of a microcapillary reactor in continuous flow mode with sunlight as the most sustainable energy source imaginable was applied to a range of photoredox and H-atom-transfer reactions making them both fast and green.

Design, synthesis and biological evaluation of novel benzimidazole-2-substituted phenyl or pyridine propyl ketene derivatives as antitumour agents

A series of novel benzimidazole-2-subsituted phenyl or pyridine propyl ketene derivatives were designed and synthesized. The biological activities of these derivatives were then evaluated as potential antitumour agents. These compounds were assayed for growth-inhibitory activity against HCT116, MCF-7 and HepG2 cell lines in vitro. The IC50 values of compounds A1 and A7 against the cancer cells were 0.06e3.64 mM and 0.04e9.80 mM, respectively. Their antiproliferative activities were significantly better than that of 5-Fluorouracil (IC50: 56.96e174.50 mM) and were close to that of Paclitaxel (IC50: 0.026 e1.53 μ M). The activity of these derivatives was over 100 times more effective than other reported structures of chalcone analogues (licochalcone A). A preliminary mechanistic study suggested that these compounds inhibit p53-MDM2 binding. Compounds A1, A7 and A9 effectively inhibited tumour growth in BALB/c mice with colon carcinoma HCT116 cells. The group administered 200 mg/kg of compound A7 showed a 74.6% tumour growth inhibition with no signs of toxicity at high doses that was similar to the inhibition achieved with the 12.5 mg/kg irinotecan positive control (70.2%). Therefore, this class of benzimidazole-2-subsituted phenyl or pyridine propyl ketene derivatives represents a promising lead structure for the development of possible p53-MDM2 inhibitors as new antitumour agents.

Light Induced C-C Coupling of 2-Chlorobenzazoles with Carbamates, Alcohols, and Ethers

A light induced, transition-metal-free C-C coupling reaction of 2-chlorobenzazoles with aliphatic carbamates, alcohols, and ethers is presented. Inexpensive reagents, namely sodium acetate, benzophenone, water, and acetonitrile, are employed in a simple reaction protocol using a cheap and widely available 25 W energy saving UV-A lamp at ambient temperature.

Stereoselective chemoenzymatic synthesis of enantiopure 1-(Heteroaryl)ethanamines by lipase-Catalysed kinetic resolutions

The efficient chemical synthesis and enzymatic kinetic resolution of a family of 1-(heteroaryl)ethanamines have been performed with lipases responsible for the preparation of nitrogenated compounds in high optical purity. Thus, Candida antarctica lipase type B has been identified as an excellent biocatalyst for the stereoselective production of the corresponding enantiomerically enriched (B)-acetamides and (S)-amines. A similar effect of the heteroatom in the cyclic ring has been observed in terms of reactivity and enantio- selectivity, with benzoxazole, benzothiazole and benzimidazole derivatives being obtained with excellent enantiopurities after one day of reaction. Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2009.

Photochemical Dehydrogenation, Ring Contraction, and Ring Expansion of Hydrogenated Derivatives of Benzoxazino-benzoxazine, Quinoxalino-quinoxaline, and Bibenzothiazole

The photochemical properties of the title compounds have been investigated and compared.The benzoxazino-benzoxazine derivatives 1 are photochemically converted into hydrogenated oxazolo derivatives.In some cases this ring contraction is accompanied by a dehydrogenation reaction whereby the heterocyclic ring system becomes aromatic.Hydrogenated quinoxalino-quinoxalines also undergo a photodehydrogenation reaction and become aromatic.However, a ring contraction yielding the the imidazolyl system does not take place.The only investigated sulfur-containing analog has different properties.The stable form is the bibenzothiazole 23 which contains a five-membered heterocyclic ring system.Photochemically 23 rearranges under ring expansion to give the benzothiazino-benzothiazine 24.

Benzazole lipoxygenase inhibiting compounds

Compounds of the formula: STR1 wherein R1 is (1) hydrogen, (2) C1 to C4 alkyl, (3) C2 to C4 alkenyl, or (4) NR2 R3, wherein R2 and R3 are independently selected from (1) hydrogen, (2) C1 to C4 alkyl and (3) hydroxyl, but R2 and R3 are not simultaneously hydroxyl; X is (1) oxygen, (2) sulfur, (3) SO2, or (4) NR4, wherein R4 is (1) hydrogen, (2) C1 to C6 alkyl, (3) C1 to C6 alkyl or (4) aroyl; A is selected from C1 to C6 alkylene and C2 to C6 alkenylene; n is 0-4; Y is selected independently at each occurrence from (1) hydrogen, (2) halogen, (3) hydroxy, (4) cyano, (5) halosubstituted alkyl, (6) C1 to C12 alkyl, (7) C2 to C12 alkenyl, (8) C1 to C12 alkoxy, (9) C3 to C8 cycloalkyl, (10) aryl, (11) aryloxy, (12) aroyl, (13) C1 to C12 arylalkyl, (14) C2 to C12 arylalkenyl, (15) C1 to C12 arylalkoxy, (16) C1 to C12 arylthioalkoxy, and substituted derivatives of (17) aryl, (18) aryloxy, (19) aroyl, (20) C1 to C12 arylalkyl, (21) C2 to C12 arylalkenyl, (22) C1 to C12 arylalkoxy, or (23) C1 to C12 arylthioalkoxy, wherein substituents are selected from halo, nitro, cyano, C1 to C12 alkyl, alkoxy, and halosubstituted alkyl; and M is hydrogen, a pharmaceutically acceptable cation, aroyl, or C1 to C12 alkoyl, are potent inhibitors of 5- and/or 12-lipoxygenase enzymes. Also disclosed are lipoxygenase inhibiting compositions and a method for inhibiting lipoxygenase.